menu search

Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...

October 22, 2023, 6:59 pm

Fda accepts sanofi's (sny) sbla for dupixent in pediatric eoe

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic ...

September 26, 2023, 9:46 am

Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 infla...

September 26, 2023, 5:29 am

An old dog with a new trick… ellodi’s apt-1011 promises eoe patients a convenient and potent treatment alternative

Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE treatment gold standard, Dupixe...

August 15, 2023, 7:40 pm

Revolo biotherapeutics announces positive topline data from phase 2a trial of ‘1104 in adults with active eosinophilic esophagitis

– Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of histologic...

April 19, 2023, 12:00 pm

Phathom's stock falls after receiving fda letters

Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received compl...

February 10, 2023, 7:59 am

Dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remiss...

January 30, 2023, 6:00 am

Phathom (phat) down on regulatory update on vonoprazan nda

Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for tre...

January 5, 2023, 12:02 pm

Sanofi (sny) dupixent gets chmp nod to eosinophilic esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic ...

December 19, 2022, 3:02 pm

Phathom pharmaceuticals reports third quarter 2022 financial results and provides business updates

Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint ...

November 8, 2022, 10:00 pm

Sanofi (sny) dupixent esophagitis kids study meets goal

Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III...

July 14, 2022, 12:24 pm

Sanofi, regeneron's dupixent gets fda nod for 4th indication (revised)

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic ...

May 25, 2022, 3:16 am

Regeneron (regn), sanofi get priority review for dupixent sbla

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic ...

April 4, 2022, 12:03 pm

Astrazeneca's experimental asthma gets an orphan drug designation for another disease

U.S.-listed shares of AstraZeneca AZN, +0.85% gained 0.3% in premarket trading on Friday after the company said an experimental asthma drug it is deve...

October 8, 2021, 8:08 am

Astrazeneca's experimental asthma gets an orphan drug designation for another disease

U.S.-listed shares of AstraZeneca AZN, +0.85% gained 0.3% in premarket trading on Friday after the company said an experimental asthma drug it is deve...

October 8, 2021, 8:08 am

Astrazeneca's experimental asthma gets an orphan drug designation for another disease

U.S.-listed shares of AstraZeneca AZN, +0.85% gained 0.3% in premarket trading on Friday after the company said an experimental asthma drug it is deve...

October 8, 2021, 8:08 am


Search within

Pages Search Results: